- Author:
Hai-xiao ZHANG
1
;
Er-lie JIANG
1
Author Information
- Publication Type:Journal Article
- Keywords: myelofibrosis; allogeneic hemopoietic stem cell transpantation; ruxolitinib
- From: Chinese Journal of Practical Internal Medicine 2019;39(02):139-142
- CountryChina
- Language:Chinese
- Abstract: Allogeneic hematopoietic stem cell transplantation(allo-HSCT) is the only therapy to cure myelofibrosis(MF) at present. This article gives a review on the following problems: who needs allo-SCT, how to choose allo-SCT in the era of ruxolitinib, the role of Ruxolitinib in the transplantation, whether allo-SCT can cure MF, and how to improve the effect of allo-SCT to guide the allo-SCT, in order for MF patients in clinical work.